Piramal Pharma’s pharma solutions business announced the expansion of its Antibody-Drug Conjugate (ADC) capabilities at the Grangemouth facility in Scotland and the investment in new Active Pharmaceutical Ingredient (API) infrastructure at the Morpeth facility in England. Together, these expansions and upgrades represent a total investment of approximately £55 million in the company's UK-based drug development and manufacturing capabilities as well as new employment opportunities for technical and operational staff.

In the first phase of the Grangemouth site expansion, two new ADC manufacturing suites, operational by Q3 2023, will be added to the existing three. The building has been designed to accommodate further expansion, with planned future phases that include a new sterile fill/finish suite dedicated to ADCs and two additional large-scale manufacturing suites capable of handling increased batch sizes. A new customer experience center is also being constructed for clients who are visiting the site during development and/or manufacturing activities. Ground preparation and piling works are well under way, with an official groundbreaking ceremony taking place on February 7^th.

PPS's Grangemouth facility boasts two significant ADC capabilities: fit-for-purpose rapid development for early clinical materials and robust, scalable late phase development to support pivotal trials and commercial launch. By combining these skills with offerings from our other thirteen global facilities, including fill/finish, payloads, and peptides, we can provide integrated ADC services to customers looking for fast, simplified solutions.

Peter DeYoung, Chief Executive Officer, Piramal Pharma Solutions said, "We are delighted to announce the capacity expansion of our Grangemouth facility in the UK. This new development will more than double our ADC production capacity, strengthening our ability to service customers throughout the entire drug lifecycle. The primary driver behind this investment is the demand for commercial ADCs, coupled with a strong pipeline for clinical materials. This growth is a validation of Piramal Pharma Solutions' strong focus on Patient centricity, its proven track record of service delivery, and the strategic initiatives and deep customer relationships."

This expansion represents an investment of 45 million pounds sterling, including a grant of £2.4 million from Scottish Enterprise, Scotland's national economic development agency.

The Grangemouth expansion, which is also client co-funded, is designed to facilitate the continued evolution of the business through the commercialization of customer products, together with satisfying the strong pipeline of early phase clinical demand. The new facility is being built on a 5-acre brownfield plot less than 100 meters from the existing site and is designed to meet the highest standards of global compliance. It is expected that this expansion will create approximately 40-50 new jobs, bringing the total number of employees at the site to more than 250. The new hires will join a highly qualified scientific, technical, and professional staff that has already grown almost 4-fold in recent years.

The investment in API capabilities at the Morpeth site, which is valued at approximately £10 million, includes new equipment, infrastructure, and utility systems. It is intended to meet increased market demand from global API customers while also improving PPS' carbon footprint by replacing obsolete equipment with new, energy-efficient alternatives. More than 400 people are employed at Morpeth, with 160 directly in API Operations, and this investment helps safeguard their future while also improving the site's environmental impact. PPS is investing £8 million directly, while the UK government is contributing £2 million to the project.